Depletion of atr selectively sensitizes atmdeficient human mammary epithelial cells to ionizing radiation and dna-damaging agents

Cell Cycle

Volumn 13, Issue 22, 2014, Pages 3541-3550

  Cui, Yuxia ^a   Palii, Stela S ^a   Innes, Cynthia L ^a   Paules, Richard S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Atm and rad3 related (atr); Dna damage response; G2 m checkpoint; Ionizing radiation; Synthetic lethality

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BLEOMYCIN; DNA; DOXYCYCLINE; ETOPOSIDE; SHORT HAIRPIN RNA; ATM PROTEIN, HUMAN; ATR PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; ATTENUATION; AUTOPHAGY; BREAST EPITHELIUM CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IONIZING RADIATION; LENTIVIRINAE; LETHALITY; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; WILD TYPE; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; SIGNAL TRANSDUCTION;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MAMMARY GLANDS, HUMAN; RADIATION TOLERANCE; RADIATION, IONIZING; SIGNAL TRANSDUCTION;

EID: 84919921642     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.960729     Document Type: Article

References (43)

1. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GCM, Lukas J, Jackson SP. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8:37-U13; PMID:16327781; http://dx.doi.org/10.1038/ncb1337
2. Zou L, Shiotani B. Single-Stranded DNA Orchestrates an ATM-to-ATR Switch at DNA Breaks. Mol Cell 2009; 33:547-58; PMID:19285939; http://dx.doi.org/ 10.1016/j.molcel.2009.01.024
3. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao ZM, Solimini N, Lerenthal Y, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316:1160-6; PMID:17525332; http://dx. doi.org/10.1126/science.1140321
4. Smith J, Tho LM, Xu NH, Gillespie DA. The ATMChk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. Advances in Cancer Research, Vol 108. SanDiego: Elsevier Academic Press Inc, 2010:73-112.
5. Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 2003; 17:615-28; PMID:12629044; http:// dx.doi.org/10.1101/gad.1067403
6. MorganMA, Parsels LA, Zhao LL, Parsels JD,DavisMA, HassanMC, ArumugarajahS,Hylander-Gans L,Morosini D, Simeone DM, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G(2) checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; PMID:20501833; http://dx.doi.org/10.1158/0008-5472. CAN-09-3573
7. Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev 2013; Rev 2014; 40(1):109-17; PMID:23583268; http://dx.doi.org/10.1016/j.ctrv.2013.03.002
8. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, McKenna WG, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012; 3:e441; PMID:23222511; http://dx. doi.org/10.1038/cddis.2012.181
9. Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today 2012; 17:194-202; PMID:22192883; http://dx.doi.org/10.1016/j.drudis.2011.12.009
10. Sultana R, Abdel-Fatah T, Perry C, Moseley P, Albarakti N, Mohan V, Seedhouse C, Chan S, Madhusudan S. Ataxia telangiectasia mutated and rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. Plos One 2013; 8(2):e57098; PMID:23451157; 10.1371/journal.pone.0057098
11. Schoppy DW, Brown EJ. Chk'ing p53-deficient breast cancers. J Clin Invest 2012; 122:1202-5; PMID:22446183; http://dx.doi.org/10.1172/JCI63205
12. Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 2011; 30:2526-33; PMID: 21258400; http://dx.doi.org/10.1038/onc.2010.624
13. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009; 23:1895-909; PMID:19608766; http://dx.doi.org/10.1101/gad.1815309
14. Palii SS, Cui YX, Innes CL, Paules RS. Dissecting cellular responses to irradiation via targeted disruptions of the ATM-CHK1-PP2A circuit. Cell Cycle 2013; 12:1105-18; PMID:23462183; http://dx.doi.org/ 10.4161/cc.24127
15. Arlander SJH, Greene BT, Innes CL, Paules RS. DNA protein kinase-dependent G(2) checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells. Cancer Res 2008; 68:89-97; PMID:18172300; http://dx.doi.org/ 10.1158/0008-5472.CAN-07-0675
16. Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME, Friedlander P, Brown KD, Gilbert J. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 2005; 41:1013-20; PMID:16139561; http://dx.doi.org/10.1016/j.oraloncology.2005.06.003
17. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75; PMID:18948947; http://dx.doi.org/10.1038/ nature07423
18. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C,Bignell G,DaviesH, Teague J, ButlerA, Edkins S, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153-8; PMID:17344846; http://dx.doi. org/10.1038/nature05610
19. Baltimore D, Brown EJ. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000; 14:397-402; PMID:10691732
20. de Klein A, Muijtjens M, van OsR, Verhoeven Y, Smit B, Carr AM, Lehmann AR, Hoeijmakers JHJ. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 2000; 10:479-82; PMID:10801416; http://dx.doi.org/10. 1016/S0960-9822(00)00447-4
21. Nam EA, Cortez D. ATR signalling:more than meeting at the fork. Biochem J 2011; 436:527-36; PMID:21615334; http://dx.doi.org/10.1042/BJ20102162
22. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011; 8:528-39; PMID:21587219; http:// dx.doi.org/10.1038/nrclinonc.2011.71
23. Amaravadi RK, Yu DN, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117:326-36; PMID:17235397; http://dx.doi.org/10.1172/JCI28833
24. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008; 68:1485-94; PMID:18316613; http://dx.doi.org/10.1158/0008-5472.CAN-07-0562
25. Chaachouay H, Ohneseit P, Toulany M, Kehlbach R, Multhoff G, Rodemann HP. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol 2011; 99:287-92; PMID:21722986; http:// dx.doi.org/10.1016/j.radonc.2011.06.002
26. Chen LH, Loong CC, Su TL, Lee YJ, Chu PM, Tsai ML, Tsai PH, Tu PH, Chi CW, Lee HC, et al. Autophagy inhibition enhances apoptosis triggered by BO-1051, an N-mustard derivative, and involves the ATM signaling pathway. Biochem Pharmacol 2011; 81:594-605; PMID:21184746; http://dx.doi.org/ 10.1016/j.bcp.2010.12.011
27. Chen SN, Rehman SK, Zhang W, Wen AD, Yao LB, Zhang JA. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta-Rev Cancer 2010; 1806:220-9; http://dx.doi.org/10.1016/j.bbcan.2010.07. 003
28. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med 2009; 13:3644-54; PMID:20196784; http://dx.doi.org/10.1111/j.1582-4934.2009.00663.x
29. Katayama M, Kawaguchi T, BergerMS, Pieper RO.DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge inmalignant glioma cells. Cell Death Diff 2007; 14:548-58; PMID:16946731; http://dx.doi.org/10.1038/sj.cdd.4402030
30. Furgason JM, Bahassi E. Targeting DNA repair mechanisms in cancer. Pharmacol Ther 2013; 137:298-308; PMID:23107892; http://dx.doi.org/10.1016/j.pharmthera. 2012.10.009
31. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352-67; PMID:22267462
32. Fang B. Development of synthetic lethality anticancer therapeutics. J Med Chem 2014; PMID:24893124; 10.1021/jm500415t
33. Kim YM, Lee YM, Park SY, Pyo H. Ataxia telangiectasia and Rad3-Related overexpressing cancer cells induce prolonged G(2) arrest and develop resistance to ionizing radiation. DNA and Cell Biol 2011; 30:219-27; PMID: 21294646; http://dx.doi.org/10.1089/dna.2010.1141
34. Lewis KA, Bakkum-Gamez J, Loewen R, French AJ, Thibodeau SN, Cliby WA. Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase I DNA damage response axis in colon cancers. Genes Chromosomes Cancer 2007; 46:1061-8; PMID:17879369; http://dx.doi.org/10.1002/gcc.20486
35. Huntoon CJ, Flatten KS, Hendrickson AEW, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 2013; 73:3683-91; PMID:23548269; http://dx.doi. org/10.1158/0008-5472.CAN-13-0110
36. Reaper PM, Griffiths MR, Long JM, Charrier JD, Mac-Cormick S, CharltonPA,Golec JMC, Pollard JR. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011; 7:428-30; PMID: 21490603; http://dx.doi.org/10.1038/nchembio.573
37. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Selfeating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8:741-52; PMID:17717517; http://dx.doi.org/10.1038/nrm2239
38. Lomonaco SL, Finniss S, Xiang CL, DeCarvalho A, Umansky F, Kalkanis SN, Mikkelsen T, Brodie C. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009; 125:717-22; PMID:19431142; http:// dx.doi.org/10.1002/ijc.24402
39. Zois CE, Koukourakis MI. Radiation-induced autophagy in normal and cancer cells Towards novel cytoprotection and radio-sensitization policies? Autophagy 2009; 5:442-50; PMID:19164950; http://dx.doi.org/ 10.4161/auto.5.4.7667
40. Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs. Molecular Oncology 2011; 5:368-73; PMID:21820372; http://dx.doi.org/ 10.1016/j.molonc.2011.07.002
41. Finlay MRV, Griffin RJ. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett 2012; 22:5352-9; PMID:22835870; http://dx.doi.org/10.1016/j.bmcl.2012. 06.053
42. Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKennaWG, Muschel RJ, Brunner TB. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther 2012; 13:1072-81; PMID:22825331; http://dx.doi.org/ 10.4161/cbt.21093
43. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites. Mol Cancer Ther 2012; 11:427-38; PMID:22203733; http://dx.doi.org/ 10.1158/1535-7163.MCT-11-0406